Latest in @CancerEpid. In Northern Italy, teh 26% of cancer patients who were not vaccinated against Covid-19 had 3.50 times higher death rates. https://t.co/clBcFp5xL8
The number of participants in population-based screenings in Japan decreased by approximately 10%–30% during the Covid pandemic. @IARCWHO@DaffodilCentre#Covid https://t.co/lTrIMUcokM
Calling all project managers in #Africa: an amazing opportunity to develop new #projectmanamgement skills through the STARS program. @PMInstitute https://t.co/rCSXskSetr
In this new @CancerEpid paper, Dr. Traci Bethea (@shelovesepi), Dr. Chiranjeev Dash (@JimmyD_2016), and Dr. Lucile Adams-Campbell examine the relationship between physical activity and #LungCancer in Black women. Check it out for ✨free✨ through May 10th! https://t.co/7fSIe32vQO
🤩Also published and available on line @CancerEpid is a paper from our collaboration with colleagues at the @IKNL on socioeconomic status and its relation with breast cancer recurrence and survival in young women in the Netherlands 🇳🇱 https://t.co/Lky8JYEjuG
@Cancerepid highlights World Cancer Day and the need to equal access to cancer diagnosis and therapeutics for children with cancer across the entire world. @cancer_dk https://t.co/nUouZ1PMLc
Count down to 4th February 2022. Elsevier and @CancerEpid proudly supports World Cancer Day. Highlighting recent @ElsevierConnect Cancer findings.
Access to essential anticancer medicines for children and adolescents. https://t.co/IaBZclElhV
Latest in @CancerEpid People with intellectual disability face multiple barriers to cancer screening. Screening provision should be augmented based on their unmet needs. Dorothy Chan et al. @rainwoodeye@cuhknursing https://t.co/fzr9kuonN1
Latest in @CancerEpid ! Individuals with anal cancer may expect similar survival regardless of HIV status. By Louise Sumner, Emiko Kamitani, Sharon chase and Ying Wang @HarvardChanSPH https://t.co/9EAtZQHDmD
Check out our new manuscript, "A National Study of Alcohol Consumption Patterns among Population-Based US Cancer Survivors Compared with Cancer-Free Individuals" in @CancerEpid
https://t.co/8sGpRcRdA0
Latest in @CancerEpid: Population-based cancer survival in the Golestan Iran by @TehUofMed and @IARCWHO. Overall 5-year net survival across was just 25%. https://t.co/iIQs6xEIOm